The fifth batch of national procurement is imminent, and 157 varieties have been included in the national procurement

According to the latest review of the WeChat public account "Fengyun Yaotan", the
four rounds of centralized procurement involved 157 varieties .
As of March 1, 2021, the varieties that have passed the consistency evaluation but have not yet been collected (according to the general There are 281 varieties in total, of which 79 varieties have passed the consistency evaluation of 3 (≥1+2 pattern), 100 varieties have passed the uniformity evaluation, and only 102 varieties have been evaluated by one pharmaceutical company ( Common name)
.
It is not difficult to see that a batch of varieties has met the requirements of the state for organizing centralized drug procurement
.
Looking back at the first four rounds of national procurement, we can see that since December 2018, the national centralized procurement has carried out four batches, with a total of 157 varieties selected, with an average decrease of 50% and a maximum of 70%
.
Specifically-the first round of 4+7, the variety of centralized procurement decreased by 50%; the expansion of 4+7, the average price reduction of the proposed selection was 59%; the second batch of centralized procurement, the average decline of varieties was 53%; the third batch of centralized procurement, The average drop of varieties was as high as 70%; the fourth batch of national procurement, the average drop of varieties was 52%
.
According to data, as of now, the first three batches of nationally organized drug procurement involve a total of 112 drugs, and the average drug price has fallen by 54%
.
Calculated according to the agreed procurement volume, the annual procurement cost has dropped from 65.
9 billion yuan to 12 billion yuan, saving 53.
9 billion yuan
.
According to statistics from Industrial Securities, as of 2020, the actual procurement volume of the three batches of national procurement has reached 2.
4 times the agreed procurement volume, and the overall cost savings have exceeded 100 billion yuan
.
Specifically, the Xinhua News Agency previously pointed out that the third batch of national procurement is calculated according to the agreed procurement volume, and the annual related costs will be reduced from 23.
2 billion yuan before centralized procurement to 3.
7 billion yuan, saving 19.
5 billion yuan
.
Recently, many provinces have issued relevant notices on the implementation of the fourth batch of national procurement
.
It is expected that the fourth batch of centralized procurement will be implemented nationwide around May .
When the results of the fourth batch of centralized procurement were officially announced, according to official preliminary estimates, the fourth batch of centralized procurement is expected to save 12.
4 billion yuan in drug costs a year
.
With the advancement of centralized procurement, the maturity of rules, and the accumulation of corporate participation experience, statistics show that the fourth batch of national procurement has a total of 152 companies participating, resulting in 118 pharmaceutical companies to be selected, and the percentage of companies to be selected is 71%, compared with Compared with the previous batches, it has improved significantly
.

　　Four rounds of centralized procurement rules and progress review
Xinhua News Agency once pointed out that there are more than 2,600 kinds of medicines in China's medical insurance catalogue, and the national organization of centralized procurement only involves more than 100 kinds
.
At present, as long as the number or amount of drugs that meet the requirements for centralized procurement reaches a certain level, it will trigger the state to organize centralized procurement
.
According to Cyber ​​Blue, the rules and progress of the four rounds of centralized procurement so far are as follows: The first round of 4+7 centralized procurement: 11 pilot cities, 25 varieties, and a 12-month procurement cycle.
Only the lowest price company is allowed to be selected; The first round of 4+7 centralized procurement, the centralized procurement document was released on November 15, 2018, and the official results were released on December 7, 2018, and the next year's February-February was successively implemented
.
4+7 expansion: covering 25 alliance regions, allowing up to 3 companies to choose to share 70% of the agreed purchase volume (1 50%, 2 60%), and the purchase cycle is up to 2 years (may be extended by one depending on the situation) (3 years in total); On September 1, 2019, the 4+7 centralized procurement expansion released the centralized procurement documents, and the results of the centralized procurement were announced on September 25, 2019.
The first round of centralized procurement was expanded to the whole country
.
The second round of centralized procurement: national participation, 32 varieties, and a maximum of 6 companies are allowed to be selected.
The procurement cycle of varieties selected by 4 or more companies is 3 years (1 for 1 year, 2 or 3 for 2 years), 4 80% of the shared agreed procurement volume selected among the above and above (50% for 1 company, 60% for 2 companies, and 70% for 3 companies); The second round of centralized procurement, the centralized procurement document issued on December 29, 2019, 2020 The results were released on January 17, and the procurement phase has been entered in April
.
The third round of centralized procurement: national participation, 55 varieties, and a maximum of 8 pharmaceutical companies are allowed to choose.
The procurement cycle of varieties selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 and above, 3 years), 80% of shared agreed purchases among 4 and above selected (50% for 1 selected, 60% for 2 selected, 70% for 3 selected); third round of centralized procurement, 2020 The centralized procurement documents were released on July 29, the official selection results were officially announced on August 24, and the results of centralized procurement were launched in many places across the country in November
.
The fourth round of centralized procurement: national participation, 45 varieties, and a maximum of 10 companies are allowed to be selected.
The procurement cycle of varieties selected by 4 or more companies is 3 years (1 or 2 companies, 1 year; 3 companies, 2 years; 4 Home and above, 3 years), 80% of the shared agreed procurement volume among 4 and above selected (1 selected 50%, 2 selected 60%, 3 selected 70%); the fourth round of centralized procurement, December 2020 On the 25th, the Shanghai Sunshine Pharmaceutical Purchasing Website officially announced that on February 8, 2021, the final selection results of the fourth batch of national sources will be announced.
According to official sources, the fourth batch of national sources is expected to land in May
.
Satisfying one of the three conditions of a fuse mechanism of 1.
8 times, a reduction of greater than or equal to 50%, and a unit comparable price of less than or equal to 0.
1 yuan is still a condition for the enterprise to obtain the qualification for the proposed selection
.
Up to now, the state has organized four batches of centralized procurement , involving a total of 157 varieties of drugs, all of which have passed the consistency evaluation of quality and efficacy
.
The range of drugs organized by the state for centralized procurement is expanding in an orderly manner .